Biopharma
ByCan Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Is Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Is Novo Nordisk’s Oral Wegovy Off to a Record Start? Early Prescription Surge Signals Strong Momentum
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded a robust debut,…
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
